- Markets
- Healthcare
- ADVENZYMES
ADVENZYMES
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Advanced Enzyme Technologies Says Unit To Form A New Corporation In California, US
Dec 5 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
UNIT TO FORM OF A NEW CORPORATION IN CALIFORNIA, US
VALUE OF ASSETS TO BE TRANSFERRED BY SEB TO STARYA LABS UPTO $500,000
Source text: ID:nBSEKTThX
Further company coverage: ADEN.NS
(([email protected];;))
Dec 5 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
UNIT TO FORM OF A NEW CORPORATION IN CALIFORNIA, US
VALUE OF ASSETS TO BE TRANSFERRED BY SEB TO STARYA LABS UPTO $500,000
Source text: ID:nBSEKTThX
Further company coverage: ADEN.NS
(([email protected];;))
India's Advanced Enzyme Technologies Sept-Quarter Consol Net Profit Rises
Nov 7 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
SEPT-QUARTER CONSOL NET PROFIT 344.1 MILLION RUPEES VERSUS PROFIT 262.1 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE5cMD4C
Further company coverage: ADEN.NS
(([email protected];))
Nov 7 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
SEPT-QUARTER CONSOL NET PROFIT 344.1 MILLION RUPEES VERSUS PROFIT 262.1 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.39 BILLION RUPEES
Source text for Eikon: ID:nBSE5cMD4C
Further company coverage: ADEN.NS
(([email protected];))
Advanced Enzyme Technologies's Unit Approves Purchase Of Entire Business Undertaking Of Shri Ganesh Industrial Enzymes
March 31 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
UNIT APPROVED PURCHASE OF ENTIRE BUSINESS UNDERTAKING OF SHRI GANESH INDUSTRIAL ENZYMES
ACQUISITION VIA SLUMP SALE ON A GOING CONCERN BASIS FOR UPTO 9 MILLION RUPEES
Source text for Eikon: ID:nBSE8mxSFX
Further company coverage: ADEN.NS
(([email protected];))
March 31 (Reuters) - Advanced Enzyme Technologies Ltd ADEN.NS:
UNIT APPROVED PURCHASE OF ENTIRE BUSINESS UNDERTAKING OF SHRI GANESH INDUSTRIAL ENZYMES
ACQUISITION VIA SLUMP SALE ON A GOING CONCERN BASIS FOR UPTO 9 MILLION RUPEES
Source text for Eikon: ID:nBSE8mxSFX
Further company coverage: ADEN.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Split
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Advanced Enzyme do?
Advanced Enzymes Technologies Limited is the largest Indian enzyme company focusing on research, development, and manufacturing of enzymes and probiotics. Their aim is to provide side-effect free healthcare solutions, improve animal nutrition, and promote enzyme-based industrial processes.
Who are the competitors of Advanced Enzyme?
Advanced Enzyme major competitors are Fermenta Biotech, Concord Biotech, Biocon, Guj. Themis Biosyn, Gufic Biosciences, Panacea Biotec, Sequent Scientific. Market Cap of Advanced Enzyme is ₹3,370 Crs. While the median market cap of its peers are ₹3,467 Crs.
Is Advanced Enzyme financially stable compared to its competitors?
Advanced Enzyme seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Advanced Enzyme pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Advanced Enzyme latest dividend payout ratio is 42.78% and 3yr average dividend payout ratio is 20.91%
How has Advanced Enzyme allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Advanced Enzyme balance sheet?
Balance sheet of Advanced Enzyme is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Advanced Enzyme improving?
Yes, profit is increasing. The profit of Advanced Enzyme is ₹137 Crs for TTM, ₹133 Crs for Mar 2024 and ₹106 Crs for Mar 2023.
Is the debt of Advanced Enzyme increasing or decreasing?
Yes, The debt of Advanced Enzyme is increasing. Latest debt of Advanced Enzyme is -₹85.58 Crs as of Sep-24. This is greater than Mar-24 when it was -₹261.29 Crs.
Is Advanced Enzyme stock expensive?
Advanced Enzyme is not expensive. Latest PE of Advanced Enzyme is 25.35, while 3 year average PE is 29.94. Also latest EV/EBITDA of Advanced Enzyme is 16.08 while 3yr average is 18.79.
Has the share price of Advanced Enzyme grown faster than its competition?
Advanced Enzyme has given lower returns compared to its competitors. Advanced Enzyme has grown at ~-21.0% over the last 1yrs while peers have grown at a median rate of 18.1%
Is the promoter bullish about Advanced Enzyme?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 43.08% and last quarter promoter holding is 42.93%.
Are mutual funds buying/selling Advanced Enzyme?
The mutual fund holding of Advanced Enzyme is decreasing. The current mutual fund holding in Advanced Enzyme is 5.36% while previous quarter holding is 5.57%.